SANTA CLARA, Calif.--Affymetrix said it will use the proceeds of a recent stock sale to expand its manufacturing capabilities, research and development facilities, and sales and marketing efforts, and for other general corporate purposes. The company announced last month that it completed a private placement of 1 million shares of common stock for an aggregate purchase of $32.5 million to the Growth Fund of America, managed by Capital Research and Management.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.